14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AKBA ranks #16304 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Akebia Therapeutics Stock Forecast NASDAQ:AKBA

$2.52 (-5.62%)

Volume: 3M

Closed: Dec 03, 2021

Hollow Logo Score: -5.354

Akebia Therapeutics Stock Forecast

$2.52 (-5.62%)

Volume: 3M

Closed: Dec 03, 2021

Score Hollow Logo -5.354
Which way will AKBA go? Request
Key Stats
Beta 1.43
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 33 and the stock is currently not being overbought or oversold

Akebia Therapeutics stock price took a fall of -5.62% on Friday
(Updated on Dec 03, 2021)


Sell candidate since 2021-11-29 Loss -3.82%

The Akebia Therapeutics stock price fell by -5.62% on the last day (Friday, 3rd Dec 2021) from $2.67 to $2.52. During the day the stock fluctuated 7.57% from a day low at $2.51 to a day high of $2.70. The price has been going up and down for this period, and there has been a -8.7% loss for the last 2 weeks. Volume has increased on the last day by 227 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 3 million shares were bought and sold for approximately $8.78 million.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($2.63) are considered to be a "second chance" to get out. According to the fan-theory $1.97 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Akebia Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.65 and $2.84. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, November 03, 2021, and so far it has fallen -24.55%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.19 between high and low, or 7.57%. For the last week, the stock has had a daily average volatility of 6.40%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Akebia Therapeutics stock A Buy?

Akebia Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.354

Predicted Opening Price for Akebia Therapeutics of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$2.58 $2.52 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 11, 2021 "HC Wainwright" gave "$6.00 - $10.00" rating for AKBA. The price target was set to $2.98+7.6%.

Volatility and Risk
Daily Average Volatility: 6.40 %
Overall Risk: Very High High Medium Low Very Low
Volatility
6.40 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $2.80
Price: $2.52
No Support Found

AKBA Insider Trading Show all Trades

INSIDER POWER

31.672

Last 100 transactions
Buy: 4 830 604 | Sell: 152 520 (Shares)
Date Action Amount Person Type
Nov 01, 2021 Buy 80 200 Frieson Ron Stock Option (Right to buy)
Sep 30, 2021 Buy 200 000 Spellman David A Employee Stock Option (Right to Buy)
Aug 31, 2021 Sell 1 042 Burke Steven Keith Common Stock
Jun 07, 2021 Sell 4 567 Gilman Steven C Common Stock
Jun 02, 2021 Buy 13 700 Wolf Myles Common Stock
Show all Insider Trades
INSIDER POWER

31.672

Last 100 transactions
Buy: 4 830 604 | Sell: 152 520 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 2.77 9.79 %
2.69 6.91 %
2.65 5.13 %
Current price: 2.52
Support 2.50 -0.63 %
2.46 -2.41 %
2.39 -5.29 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 2.87 13.89 %
2.86 13.49 %
2.80 11.11 %
Current price 2.52
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT